Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.

Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, Dillhoff M, Schmidt CR, Shirley LA.

Ann Surg Oncol. 2018 Nov;25(12):3613-3620. doi: 10.1245/s10434-018-6741-x. Epub 2018 Sep 4.

PMID:
30182331
2.

Pancreastatin predicts survival in neuroendocrine tumors.

Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2014 Sep;21(9):2971-80. doi: 10.1245/s10434-014-3728-0. Epub 2014 Apr 22.

3.

Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.

Desai DC, O'Dorisio TM, Schirmer WJ, Jung SS, Khabiri H, Villanueva V, Martin EW.

Regul Pept. 2001 Jan 12;96(3):113-7.

PMID:
11111016
4.

Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.

Dhir M, Shrestha R, Steel JL, Marsh JW, Tsung A, Tublin ME, Amesur NB, Orons PD, Santos E, Geller DA.

Ann Surg Oncol. 2017 Feb;24(2):450-459. doi: 10.1245/s10434-016-5591-7. Epub 2016 Sep 23.

PMID:
27663565
5.

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.

Stronge RL, Turner GB, Johnston BT, McCance DR, McGinty A, Patterson CC, Ardill JE.

Ann Clin Biochem. 2008 Nov;45(Pt 6):560-6. doi: 10.1258/acb.2008.008033. Epub 2008 Sep 9.

PMID:
18782815
6.

Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.

Khan TM, Garg M, Warner RR, Uhr JH, Divino CM.

Pancreas. 2016 Aug;45(7):1032-5. doi: 10.1097/MPA.0000000000000572.

PMID:
26684860
7.

Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.

Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A.

Endocrine. 2014 Sep;47(1):177-82. doi: 10.1007/s12020-013-0130-9. Epub 2014 Jan 3.

PMID:
24385266
8.

Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.

Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C.

Asia Pac J Clin Oncol. 2016 Mar;12(1):61-9. doi: 10.1111/ajco.12438. Epub 2015 Dec 14.

PMID:
26663886
9.

Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review.

Shirley LA, McNally M, Chokshi R, Jones N, Tassone P, Guy G, Khabiri H, Schmidt C, Shah M, Bloomston M.

World J Surg Oncol. 2015 May 1;13:167. doi: 10.1186/s12957-015-0551-4.

10.

Serum pancreastatin: the next predictive neuroendocrine tumor marker.

Rustagi S, Warner RR, Divino CM.

J Surg Oncol. 2013 Aug;108(2):126-8. doi: 10.1002/jso.23359. Epub 2013 Jun 15.

PMID:
23775817
11.

Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.

Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, Hwang W, Sze DY, Kothary N, Stashek K, Wileyto EP, Salem R, Metz DC, Soulen MC.

Cardiovasc Intervent Radiol. 2017 Jan;40(1):69-80. doi: 10.1007/s00270-016-1478-z. Epub 2016 Oct 13.

PMID:
27738818
12.

Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.

Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, Gregory G, Khabiri H, Shah M, Bloomston M.

Ann Surg Oncol. 2013 Apr;20(4):1114-20. doi: 10.1245/s10434-012-2786-4. Epub 2013 Mar 2.

PMID:
23456380
13.

Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution.

Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O'Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR.

Pancreas. 2014 Mar;43(2):219-25. doi: 10.1097/MPA.0000000000000030.

14.

Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.

Onesti JK, Shirley LA, Saunders ND, Davidson GW, Dillhoff ME, Khabiri H, Guy GE, Dowell JD, Schmidt CR, Shah MH, Bloomston M.

J Gastrointest Surg. 2016 Mar;20(3):580-6. doi: 10.1007/s11605-015-2998-6. Epub 2015 Oct 21.

PMID:
26489743
15.

Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.

O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G.

Pancreas. 2010 Jul;39(5):611-6. doi: 10.1097/MPA.0b013e3181c68d7a.

PMID:
20124939
16.

Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center.

Kavecansky J, Wei L, Caronia L, Ramirez MT, Bloomston M, Shah MH.

Pancreas. 2015 Mar;44(2):198-203. doi: 10.1097/MPA.0000000000000267.

PMID:
25411805
17.

Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.

Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, Kim WH.

J Vasc Interv Radiol. 2013 Jul;24(7):947-56; quiz 957. doi: 10.1016/j.jvir.2013.02.030. Epub 2013 Apr 19.

PMID:
23602421
19.

Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?

Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R.

Radiology. 2017 Jun;283(3):883-894. doi: 10.1148/radiol.2016160838. Epub 2016 Nov 10.

20.

Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.

Kim SS, Cho HJ, Won JH, Bae JI, Kang DR, Lee JD, Shin SJ, Lee KM, Yoo BM, Kim JK, Lee JH, Ahn SJ, Park JH, Cho SW, Cheong JY.

Cytokine. 2015 Dec;76(2):449-457. doi: 10.1016/j.cyto.2015.07.001. Epub 2015 Jul 8.

PMID:
26163999

Supplemental Content

Support Center